Eczacıbaşı İlaç (ECILC) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of Eczacıbaşı İlaç (ECILC) in the İlaç ve Sağlık sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: Eczacıbaşı İlaç
- Ticker: ECILC
- Sector: İlaç ve Sağlık
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 2.6 / 5
- Profitability: 2.4 / 5
- Liquidity: 2.4 / 5
- Leverage: 3.9 / 5
- Efficiency: 1.6 / 5
Summary Income Statement (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Revenue | 5,179 | 5,725 | -9.5% |
| Gross Profit | 1,959 | 1,660 | +18.0% |
| Operating Profit | -216 | 214 | -200.5% |
| EBITDA | 0 | 0 | — |
| Net Monetary Position Gains | -91 | 190 | -148.0% |
| Net Profit for the Period | -1,855 | 2,549 | -172.8% |
Summary Balance Sheet (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Current Assets | 7,774 | 9,227 | -15.7% |
| Non-Current Assets | 77,098 | 56,325 | +36.9% |
| Total Assets | 84,873 | 65,552 | +29.5% |
| Current Liabilities | 5,280 | 4,279 | +23.4% |
| Non-Current Liabilities | 10,775 | 8,326 | +29.4% |
| Total Liabilities | 16,055 | 12,605 | +27.4% |